Learn / Clinical Research Management / Regulation, ethics review and informed consent
Regulatory and ethics approvals in Uganda and the region
13 minute read · 6-question quiz
What you will learn
List the approvals a clinical trial typically needs in Uganda
Explain the roles of the research ethics committee, the national council and the drug regulator
Describe the submission, review, amendment and continuing review cycle
Every clinical trial needs permission from several independent bodies before the first participant is enrolled. The exact requirements change over time and differ by country, so teams must always check the current rules. This lesson describes the typical pattern in Uganda as a guide.
Typical approvals for a trial of a medicine or vaccine
- Research ethics committee (REC) approval: an institutional or independent REC accredited to review human research reviews the protocol, consent forms, investigator qualifications, recruitment materials and budget. Many institutions have their own RECs, such as university and hospital committees.
- Uganda National Council for Science and Technology (UNCST) registration: research involving human participants must be registered with the national council, which also oversees research regulation and, for foreign researchers, additional permissions.
- National Drug Authority (NDA) authorisation: clinical trials of medicines, vaccines and some devices need regulatory approval, including import permits for investigational products and review of safety reports.
- Local permissions: district health officers and local leaders where the study takes place.
- Trial registration: registering the trial in a public registry such as the Pan African Clinical Trials Registry or ClinicalTrials.gov before the first participant is enrolled, as required by the ICMJE for later publication.
What a REC reviews
- Scientific validity and the question's importance.
- Risks and benefits and how they are minimised.
- Selection of participants and fair recruitment.
- The consent process and documents, in language participants understand.
- Privacy and confidentiality, including data protection under the Data Protection and Privacy Act, 2019.
- Compensation and treatment for injury, payments and incentives (which must not be coercive).
- Qualifications of the investigators and suitability of the site.
- Community engagement and post-trial plans.
After approval
Approval is not permanent. The protocol team must:
- Submit amendments before implementing changes (except to eliminate immediate hazards).
- Submit safety reports as required, such as serious unexpected events.
- Submit progress reports and apply for annual continuing review, which lapses if not renewed.
- Report deviations and violations, and inform the REC of early termination.
- Provide a final report and, where required, share results with participants and the community.
Summary
Trials need REC approval, national registration, regulatory authorisation and trial registry entry before enrolment.
RECs review science, risk, consent, privacy, compensation and investigator qualifications.
Approval continues through amendments, safety reports, annual review and final reporting.
Plan realistic start-up timelines of months, not weeks.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.